TAILORED-CHIP Trial: Time-Dependent Antiplatelet Therapy in High-Risk PCI
Ahmed Bennis, Professor of Cardiology, shared a post on X:
”Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial
TAILORED-CHIP trial is an investigator-initiated, multicentre, prospective randomised trial to evaluate the efficacy and safety of a time-dependent tailored antiplatelet therapy with an early (<6 months post-PCI) escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin) and a late (>6 months post-PCI) de-escalation (clopidogrel monotherapy) in patients undergoing complex high-risk PCI as compared with standard DAPT (clopidogrel plus aspirin for 12 months).”
Read the full article here.
Title: Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial
Authors: Hanbit Park, Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Kyoung-Ha Park, Se-Hun Kang, Jon Suh, Jang-Whan Bae, Sangwoo Park, Jang Hyun Cho, Jung-Won Suh, Bong-Ki Lee, Seung-Woon Rha, Hoyoun Won, Jae-Sik Jang, Moo Hyun Kim, Cheol Hyun Lee, Young Keun Ahn, Jun-Hyok Oh, Jae-Seok Bae, Chul Soo Park, Jaewoong Choi, Jin-Bae Lee, Se-Whan Lee, Sung-Ho Hur, Osung Kwon, Seung-Jung Park, Duk-Woo Park; on behalf of the TAILORED-CHIP trial investigators
Stay updated with Hemostasis Today.
-
Aug 21, 2025, 16:16Reza Shojaei on Redefining Blood Waste: The Future of Biotech and Healing
-
Aug 21, 2025, 16:01TAILORED-CHIP Trial: Time-Dependent Antiplatelet Therapy in High-Risk PCI
-
Aug 21, 2025, 15:54On the Chessboard of Blood Donation: Abdul Mannan Reviews a Complex Case
-
Aug 21, 2025, 15:31Flora Peyvandi on AI in Clinical Supervision: Educational Strategies
-
Aug 21, 2025, 15:28Lumbar Puncture Safety in Blood Cancers: Study Supports Platelet Count of 40 Instead of 50 - Haematologica
-
Aug 21, 2025, 15:48World Federation of Hemophilia on Inhibitors in Treatment
-
Aug 21, 2025, 14:00Wolfgang Miesbach, Flora Peyvandi and Glenn F Pierce on Malignancy in Persons with Haemophilia
-
Aug 20, 2025, 14:25Mattia Galli: Sex-related Differences in Platelet Reactivity in Patients Both On and Off Antiplatelet Therapy
-
Aug 20, 2025, 12:55Commentary from Giuseppe Lippi and Colleagues on Light Exposure, Platelet Function and Thrombus Formation
-
Aug 20, 2025, 05:48James Harte on Asundexian and Milvexian's Strong, Dose-dependent Interferences in Coagulation Assays
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025